89 related articles for article (PubMed ID: 11573240)
1. Butyrate stimulates ApoA-IV-containing lipoprotein secretion in differentiated Caco-2 cells: role in cholesterol efflux.
Nazih H; Nazih-Sanderson F; Krempf M; Michel Huvelin J; Mercier S; Marie Bard J
J Cell Biochem; 2001 Aug 1-9; 83(2):230-8. PubMed ID: 11573240
[TBL] [Abstract][Full Text] [Related]
2. Human ApoA-IV overexpression in transgenic mice induces cAMP-stimulated cholesterol efflux from J774 macrophages to whole serum.
Fournier N; Atger V; Paul JL; Sturm M; Duverger N; Rothblat GH; Moatti N
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1283-92. PubMed ID: 10807744
[TBL] [Abstract][Full Text] [Related]
3. Modulation of lipid synthesis, apolipoprotein biogenesis, and lipoprotein assembly by butyrate.
Marcil V; Delvin E; Seidman E; Poitras L; Zoltowska M; Garofalo C; Levy E
Am J Physiol Gastrointest Liver Physiol; 2002 Aug; 283(2):G340-6. PubMed ID: 12121881
[TBL] [Abstract][Full Text] [Related]
4. Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alpha-migrating high-density lipoprotein particles.
Asztalos B; Zhang W; Roheim PS; Wong L
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1630-6. PubMed ID: 9327755
[TBL] [Abstract][Full Text] [Related]
5. ApoA-IV is secreted on discrete HDL particles by the rat hepatoma cell line McA-RH7777 transfected with ApoA-IV cDNA.
Yao Z; Lauer SJ; Sanan DA; Fazio S
Arterioscler Thromb; 1993 Oct; 13(10):1476-86. PubMed ID: 8399085
[TBL] [Abstract][Full Text] [Related]
6. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
[TBL] [Abstract][Full Text] [Related]
7. Structure and function of the apoA-IV T347S and Q360H common variants.
Gomaraschi M; Putt WE; Pozzi S; Iametti S; Barbiroli A; Bonomi F; Favari E; Bernini F; Franceschini G; Talmud PJ; Calabresi L
Biochem Biophys Res Commun; 2010 Feb; 393(1):126-30. PubMed ID: 20117098
[TBL] [Abstract][Full Text] [Related]
8. Identification of a sequence of apolipoprotein A-I associated with the efflux of intracellular cholesterol to human serum and apolipoprotein A-I containing particles.
Sviridov D; Pyle L; Fidge N
Biochemistry; 1996 Jan; 35(1):189-96. PubMed ID: 8555173
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-IV expression in mouse liver enhances triglyceride secretion and reduces hepatic lipid content by promoting very low density lipoprotein particle expansion.
VerHague MA; Cheng D; Weinberg RB; Shelness GS
Arterioscler Thromb Vasc Biol; 2013 Nov; 33(11):2501-8. PubMed ID: 24030551
[TBL] [Abstract][Full Text] [Related]
10. Butyrate impairs lipid transport by inhibiting microsomal triglyceride transfer protein in Caco-2 cells.
Marcil V; Delvin E; Garofalo C; Levy E
J Nutr; 2003 Jul; 133(7):2180-3. PubMed ID: 12840175
[TBL] [Abstract][Full Text] [Related]
11. Recombinant proapoA-I(Lys107del) shows impaired lipid binding associated with reduced binding to plasma high density lipoprotein.
Huang W; Matsunaga A; Li W; Han H; Hoang A; Kugi M; Koga T; Sviridov D; Fidge N; Sasaki J
Atherosclerosis; 2001 Nov; 159(1):85-91. PubMed ID: 11689210
[TBL] [Abstract][Full Text] [Related]
12. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT
Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569
[TBL] [Abstract][Full Text] [Related]
13. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport.
Jin FY; Kamanna VS; Kashyap ML
Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):2020-8. PubMed ID: 9351367
[TBL] [Abstract][Full Text] [Related]
14. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.
Chiesa G; Parolini C; Canavesi M; Colombo N; Sirtori CR; Fumagalli R; Franceschini G; Bernini F
Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1417-23. PubMed ID: 9743230
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.
Miettinen HE; Jauhiainen M; Gylling H; Ehnholm S; Palomäki A; Miettinen TA; Kontula K
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3021-32. PubMed ID: 9409289
[TBL] [Abstract][Full Text] [Related]
16. Lipoproteins containing apolipoprotein A-IV but not apolipoprotein A-I take up and esterify cell-derived cholesterol in plasma.
von Eckardstein A; Huang Y; Wu S; Sarmadi AS; Schwarz S; Steinmetz A; Assmann G
Arterioscler Thromb Vasc Biol; 1995 Oct; 15(10):1755-63. PubMed ID: 7583553
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein A-IV: A potential therapeutic target for atherosclerosis.
Peng J; Li XP
Prostaglandins Other Lipid Mediat; 2018 Nov; 139():87-92. PubMed ID: 30352313
[TBL] [Abstract][Full Text] [Related]
18. Clearance of cationized LDL cholesterol from a muscle depot is not enhanced in human apolipoprotein A-IV transgenic mice.
Stein Y; Stein O; Duverger N; Halperin G; Dabach Y; Hollander G; Ben-Naim M
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):179-84. PubMed ID: 10634815
[TBL] [Abstract][Full Text] [Related]
19. Modification of the cholesterol efflux properties of human serum by enrichment with phospholipid.
Jian B; de la Llera-Moya M; Royer L; Rothblat G; Francone O; Swaney JB
J Lipid Res; 1997 Apr; 38(4):734-44. PubMed ID: 9144088
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of apolipoprotein A-IV enhances lipid transport in newborn swine intestinal epithelial cells.
Lu S; Yao Y; Meng S; Cheng X; Black DD
J Biol Chem; 2002 Aug; 277(35):31929-37. PubMed ID: 12070145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
